MBMeenu Bajpai

Meenu Bajpai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meenu Bajpai has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Do we need robust fire safety systems at the blood centers; Learnings from incidence

    by Ashish Maheshwari, Yajhitha R. Chintala, Meenu Bajpai

    An abstract is unavailable. This article is available as a PDF only.

  • Large volume plasmapheresis using a single‐use immunoadsorption column: A cost‐effective approach for desensitization in ABO‐incompatible liver transplant

    by Sarika Agarwal, Ashish Maheshwari, Meenu Bajpai

    Introduction: Liver transplant is a life‐saving treatment, but due to the limited availability of suitable liver donors, ABO‐incompatible liver transplants (ABOi‐LT) are conducted to increase the availability of liver donors. Perioperative desensitization for ABOi‐LT is an established strategy to circumvent the risk of graft rejection. A single prolonged session can be performed to achieve the desired titers to avoid using multiple immunoadsorption (IA) columns or off‐label reuse of single‐use columns. This study retrospectively assessed the effectiveness of a single prolonged plasmapheresis session using IA as a desensitization strategy in live donor liver transplant (LDLT).Materials and methods: This retrospective observational study conducted at a center for liver diseases in North India on six ABOi‐LDLT patients who underwent single prolonged IA sessions in the perioperative period from January 2018 to June 2021.Results: Median baseline titer in patients was 320 (64, 1024). The median plasma volume adsorbed was 7.5 volumes (4, 8) per procedure, with a mean procedure time of 600 min (310‐753). The reduction in titer ranged from 4 log to 7 log reduction per procedure. Two patients developed transient hypotension during the procedure, which was managed successfully. The median duration of pre‐transplant hospital stay was 1.5 days (1, 3).Conclusion: Desensitization therapy helps overcome the ABO barrier and decreases the waiting period before a transplant when ABO identical donors are unavailable. A single prolonged IA session reduces the cost of additional IA columns and hospital stay, thus making it a cost‐effective approach to desensitization.


  • Open Access

    Delayed adverse reactions in whole blood donors

    by Abhaykumar Malind Gupta, Meenu Bajpai

    Background & objectives: The information available regarding delayed adverse donor reactions (D-ADRs) is limited. Proactive follow up of donors for delayed reactions is not done routinely. This study was undertaken to analyze frequency and type of D-ADRs in whole blood donors as also the contributory factors. Methods: In this prospective observational study, all eligible whole blood donors were contacted telephonically twice (24 h and 2 wks after donation) and asked about general health and ADR specific questions. The International Society of Blood Transfusion standard guidelines were used to categorize ADRs. Results: The ADR data of 3514 donors were analyzed in the study. D-ADRs were more common as compared to immediate delayed adverse donor reactions (I-ADRs) (13.7 vs. 2.9%, Pvs. 12.5%, P=0.002). Females were more prone to D-ADRs (17 vs. 13.6%). Localized D-ADRs were more frequent as compared to systemic D-ADRs (Pvs. 7.37%, P<0.001). Interpretation & conclusions: D-ADRs were more common than I-ADRs with a different profile. First time, female and young donors were more prone to D-ADRs. These categories need special care at the time of blood donation. Active follow up of blood donors should be done from time to time to strengthen donor safety.


  • Immune predictors of hepatitis B surface antigen seroconversion in patients with hepatitis B reactivation

    by Mojahidul Islam, Jayesh Kumar Sevak, Manoj Kumar Sharma, Ankur Jindal, Ashish Kumar Vyas, Meenu Bajpai, Gayatri Ramakrishna, Shiv Kumar Sarin, Nirupma Trehanpati

    Summary: Background: Hepatitis B surface antigen (HBsAg) seroconversion is sometimes observed in hepatitis B reactivation (rHBV), probably due to immune resetting and differentiation.Aims: To investigate sequential immune differentiation and abrogation of tolerance in patients with rHBV who achieved HBsAg seroconversion.Methods: We included 19 patients with chronic hepatitis B (CHBV; HBV DNA log103‐8), 67 with rHBV (raised ALT [>5XULN], HBV DNAlog104‐8) and 10 healthy controls. Immune differentiation, tolerance and functional status of CD4, CD8, T regulatory cells (Tregs), B cells and follicular T helper (Tfh) cells were assessed at baseline and 24 weeks.Results: At 24 weeks, 81% rHBV (n = 67) lost HBV DNA and HBeAg (41%), and 12 (19%) lost HBsAg and made anti‐HBs titers >10 IU/ml. rHBV patients had higher Th1/17, TEM, Tfh, Tfh1/17, plasma and ATM B cells, and lower Tregs, Th2, Th17 and TEMRA expression. rHBV showed lower PD1, TIM3, LAG3, SLAM and TOX compared to CHBV. There was a significant increase in CD8, CD8EM, Tfh, Tfh1/17 and plasma B cells in seroconverters than non‐seroconverters. At 24 weeks, we also observed increased plasma B cell frequency in seroconverters. While non‐seroconverters showed higher expression of PD1, TIM3, LAG3, SLAM and TOX on CD4/CD8 T cells, blockade of PD1, TIM3, LAG3 and CTLA4 significantly enhanced IFN‐γ, TNF‐α, IL‐4 and IL‐21 expression on CD4/CD8 and Tfh cells in non‐seroconverters.Conclusions: Non‐seroconverters have increased inhibitory markers on CD4/CD8 T cells. There is a critical play of CD8, Tfh and B cells and subsets in seroclearance, along with checkpoint molecules as a potential therapy for non‐seroconverters in HBV infection.


  • Ichthyosis in blood donors

    by Ashish Maheshwari, Somesh Gupta, Meenu Bajpai

  • Open Access

    Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients

    by Meenu Bajpai, Ashish Maheshwari, Suresh Kumar, Karan Chhabra, Pratibha Kale, Ashad Narayanan, Amita Gupta, Ekta Gupta, Nirupama Trehanpati, Reshu Agarwal, et al.

    Background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease. Results: The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.


  • Open Access

    Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers

    by Pratibha Kale, Ekta Gupta, Chhagan Bihari, Niharika Patel, Sheetalnath Rooge, Amit Pandey, Meenu Bajpai, Vikas Khillan, Partha Chattopadhyay, Priti Devi, et al.

    This study elucidated the clinical, humoral immune response and genomic analysis of vaccine breakthrough (VBT) infections after ChAdOx1 nCoV-19/Covishield vaccine in healthcare workers (HCWs). Amongst 1858 HCWs, 1639 had received either two doses (1346) or a single dose (293) of ChAdOx1 nCoV-19 vaccine. SARS-CoV-2 IgG antibodies and neutralizing antibodies were measured in the vaccinated group and the development of SARS-CoV-2 infection was monitored.Forty-six RT-PCR positive samples from the 203 positive samples were subjected to whole genome sequencing (WGS). Of the 203 (10.92%) infected HCWs, 21.46% (47/219) were non-vaccinated, which was significantly more than 9.52% (156/1639) who were vaccinated and infection was higher in doctors and nurses. Unvaccinated HCWs had 1.57 times higher risk compared to partially vaccinated HCWs and 2.49 times higher risk than those who were fully vaccinated.The partially vaccinated were at higher risk than the fully vaccinated (RR 1.58). Antibody non-response was seen in 3.44% (4/116), low antibody levels in 15.51% (18/116) and medium levels were found in 81.03% (94/116). Fully vaccinated HCWs had a higher antibody response at day 42 than those who were partially vaccinated (8.96 + 4.00 vs. 7.17 + 3.82). Whole genome sequencing of 46 samples revealed that the Delta variant (B.1.617.2) was predominant (69.5%). HCWs who had received two doses of vaccine showed better protection from mild, moderate, or severe infection, with a higher humoral immune response than those who had received a single dose. The genomic analysis revealed the predominance of the Delta variant (B.1.617.2) in the VBT infections.


  • Open Access

    Isolated erythrocytosis: A consequence of COVID‐19 induced hypoxia

    by Ashish Maheshwari, Guru Priya, Meenu Bajpai